Department of Gastroenterology, Zhongshan Hospital of Fudan University, Room 207, Building 3, Zhongshan Hospital, Fenglin Road 180#, Xuhui District, Shanghai, China.
Department of Geriatrics, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
BMC Cancer. 2018 Apr 13;18(1):415. doi: 10.1186/s12885-018-4343-4.
Many novel diagnostic biomarkers have been developed for gastric cancer (GC) recently. We chose two methods with high diagnostic value, the detection of serum microRNAs and metabolomics based on gas chromatography/mass spectrometry (GC/MS), and aimed to establish appropriate models.
We reviewed the diagnostic accuracies of all microRNAs identified by previous diagnostic tests. Then appropriate microRNAs and their combinations were validated the diagnostic value. We included 80 patients with GC and 82 healthy controls (HCs) and detected the expression of the microRNAs. GC/MS analysis was conducted, and we used three multivariate statistical analyses to establish diagnostic models. The concentrations of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were detected for comparison with the novel models.
Sixty-seven published studies and 70 microRNAs were finally included in the systematic review. MiR-18a, miR-19a, miR-21, miR-92a, miR-199a and miR-421 were chosen to further validate their diagnostic efficiencies. Five of those microRNAs in GC patients had significantly different expression. The combination of miR-19a and miR-92a had the highest area under the curve (AUC) at 0.850 with a sensitivity of 91.3% and a specificity of 61.0%. The GC/MS analysis performed an excellent diagnostic value and the AUC reached 1.0.
There is a good potential for microRNAs and GC/MS analysis as new diagnostic methods in view of their high diagnostic value compared with traditional biomarkers.
最近已经开发出许多用于胃癌（GC）的新型诊断生物标志物。我们选择了两种具有高诊断价值的方法，即血清 microRNAs 的检测和基于气相色谱/质谱（GC/MS）的代谢组学，并旨在建立合适的模型。
我们回顾了以前的诊断测试中确定的所有 microRNAs 的诊断准确性。然后，适当的 microRNAs 及其组合被验证了其诊断价值。我们纳入了 80 例 GC 患者和 82 例健康对照者（HCs），并检测了 microRNAs 的表达。进行了 GC/MS 分析，并使用三种多元统计分析方法建立了诊断模型。检测癌胚抗原（CEA）和碳水化合物抗原 19-9（CA19-9）的浓度，与新模型进行比较。
最终纳入了 67 项已发表的研究和 70 个 microRNAs 进行系统评价。选择 miR-18a、miR-19a、miR-21、miR-92a、miR-199a 和 miR-421 进一步验证其诊断效率。在 GC 患者中，其中 5 个 microRNAs 的表达有显著差异。miR-19a 和 miR-92a 的组合具有最高的曲线下面积（AUC）为 0.850，灵敏度为 91.3%，特异性为 61.0%。GC/MS 分析具有出色的诊断价值，AUC 达到 1.0。
鉴于与传统生物标志物相比，microRNAs 和 GC/MS 分析具有较高的诊断价值，因此它们作为新的诊断方法具有良好的潜力。
